{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-324463","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.183613+00:00","generated_at":"2026-06-28T10:43:33.515203+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"REGENXBIO closes $370M upfront eye care collaboration with AbbVie for RGX-314 gene therapy","bullets":["Upfront payment of $370M; potential for up to $1.38B in development, regulatory, and commercial milestones.","REGENXBIO and AbbVie to share equally in US profits; AbbVie to pay tiered royalties on ex-US net sales.","REGENXBIO responsible for ongoing trials; AbbVie leads global clinical development and commercialization.","REGENXBIO to lead manufacturing for clinical and US commercial supply; AbbVie for ex-US commercial supply.","Agreement covers RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-324463","json":"https://secwatch.observer/filing/0001193125-21-324463.json","markdown":"https://secwatch.observer/filing/0001193125-21-324463.md","text":"https://secwatch.observer/filing/0001193125-21-324463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/0001193125-21-324463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/d257796d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:43:33.515203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}